Jakarta, CNBC Indonesia – Not many know, Indonesia is now trying to meet the need for Covid-19 drugs by producing its own. This drug is produced by BUMN Pharmaceuticals, namely PT Kimia Farma Tbk and PT Indofarma Tbk.
Kimia Farma has produced a drug for handling Covid-19 Favipiravir or avigan. Kimia Farma through its subsidiary PT Phapros Tbk has also succeeded in producing several drugs for handling Covid-19, including Chloroquine, Hydroxychloroquine, Azithromycin, Favipiravir, Dexamethasone and Methylprednisolone.
Kimia Farma also produces several endurance enhancing multivitamins such as Vitamin C (tablets and injection), Becefort, Fituno and Geriavita as additional products to maintain endurance.
“For the type of Favipiravir drug that can be used for Covid-19 therapy, Kimia Farma can produce itself, and is the first product in Indonesia to be developed by BUMN,” said Verdi Budidarmo, the President Director of Kimia Farma in a press statement, Monday (5 / 10/2020).
Indofarma is ready to market the anti-corona drug Remdesivir under the trade name DesremTM. This drug is manufactured by Mylan Laboratories Limited, under license from Gilead Sciences Inc, Foster City and the United States of America.
In addition, Indofarma also produces its own superior antiviral Oseltamivir 75 gr which is used for the treatment of Covid-19 patients.
“The product that we will market in the near future is DesremTM Remdesivir Inj 100mg, which has received Emergency Use Authorization (EUA) approval in Indonesia and has been approved by BPOM through the issuance of a Marketing Permit Number which was issued on September 30, 2020,” said Arief Pramuhanto. , President Director of Indofarma.
“DesremTM Remdesivir Inj 100mg will go on sale next week, a drug used for inpatients with Covid-19 in moderate to severe conditions. Then for stock availability for this month, there are already +/- 400,000 vials at a price that is of course. affordable to the public. “
(roy/miq)
– .
